Lyon-based biotech startup PK MED, which specializes in the innovative development of custom-designed, injectable, and biodegradable micro-implants, has raised €1.5 million in non-dilutive DeepTech financing to advance a local cell-homing implant aimed at enhancing bone marrow transplantation.
- Founded in 2019 by Truffle Capital, PK MED develops custom injectable and biodegradable micro-implants to enhance drug delivery in rheumatology and improve bone marrow transplantation outcomes. The startup has also launched projects targeting significant medical conditions, including gout (PKM-01) and hematopoietic stem cell transplants (PKM-02).
- In PK MED's PKM-02 project, a therapeutic implant is injected directly into the patient's bone marrow before allogeneic hematopoietic stem cell transplantation (HSCT). This helps the transplanted cells find their home and become part of the body's cells.
Details of the deal
- The non-dilutive DeepTech financing came from Bpifrance, a public investment bank based in Paris that supports startups and public offerings by providing financing and investment solutions.
- With this new funding, PK MED will accelerate its PKM-02 project, an innovative cell-homing technology designed to improve bone marrow transplantation for diseases with high unmet medical needs, such as leukemia and hemoglobin disorders.
“The development of our local cell-homing implant and the support of Bpifrance are a proof of PK MED's technological excellence and its commitment to medicine. Our ambition is to significantly advance bone marrow transplantation and cell regeneration techniques, for the benefit of all patients with hematologic disorders,” CEO of PK MED, Gauthier Pouliquen, commented.
